Association of NT-proBNP and interleukin-17 levels with heart failure in elderly patients

Genetics and Molecular Research

Volumn 15, Issue 2, 2016, Pages

  Li, X F ^a   Pan, D ^b   Zhang, W L ^c   Zhou, J ^d   Liang, J J ^e  

^a LIAOCHENG PEOPLE'S HOSPITAL   (China)

^b Department of Cardiology   (China)

^c The Third People s Hospital of Liaocheng   (China)

^d Liaocheng Vocational Technical College   (China)

^e THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Congestive heart failure; Interleukin 17; N terminal pro brain natriuretic peptide

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; INTERLEUKIN 17; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; IL17A PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGED; AGING; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PROTEIN BLOOD LEVEL; RISK FACTOR; BLOOD; CASE CONTROL STUDY; CHINA; GENETICS; HEART; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; CASE-CONTROL STUDIES; CHINA; FEMALE; HEART; HEART FAILURE; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84968867618     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/gmr.15028014     Document Type: Article

References (23)

1. Cameron VA and Ellmers LJ (2003). Minireview: natriuretic peptides during development of the fetal heart and circulation. Endocrinology 144: 2191-2194. http://dx.doi.org/10.1210/en.2003-0127
2. Eid RE, Rao DA, Zhou J, Lo SF, et al. (2009). Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 119: 1424-1432. http://dx.doi.org/10.1161/CIRCULATIONAHA.108.827618
3. Flavell C and Stevenson LW (2001). Take heart with heart failure. Circulation 104: e89-e91. http://dx.doi.org/10.1161/ hc4301.099136
4. Galinier M, Berry M, Delmas C and Fournier P (2013). [Interest of NT-proBNP in chronic heart failure follow-up]. Ann. Biol. Clin. (Paris) 71: 39-45.
5. Hu MH, Zheng QF, Jia XZ, Li Y, et al. (2014). Neuroprotection effect of interleukin (IL)-17 secreted by reactive astrocytes is emerged from a high-level IL-17-containing environment during acute neuroinflammation. Clin. Exp. Immunol. 175: 268-284. http://dx.doi.org/10.1111/cei.12219
6. Krstić J, Jauković A, Mojsilović S, Ðorđević IO, et al. (2013). In vitro effects of IL-17 on angiogenic properties of endothelial cells in relation to oxygen levels. Cell Biol. Int. 37: 1162-1170.
7. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, et al. (2009). N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J. Am. Coll. Cardiol. 55: 53-60. http://dx.doi.org/10.1016/j. jacc.2009.02.095
8. Lang CC and Struthers AD (2013). Targeting the renin-angiotensin-aldosterone system in heart failure. Nat. Rev. Cardiol. 10: 125-134. http://dx.doi.org/10.1038/nrcardio.2012.196
9. Lee JH, Cho ML, Kim JI, Moon YM, et al. (2009). Interleukin 17 (IL-17) increases the expression of Toll-like receptor-2, 4, and 9 by increasing IL-1beta and IL-6 production in autoimmune arthritis. J. Rheumatol. 36: 684-692. http:// dx.doi.org/10.3899/jrheum.080169
10. Li N, Bian HJ, Zhang J and Ji XP (2010). Detection and significance of Th17 and Treg cells in patients with chronic heart failure. J. Shandong Univ. 411: 1963-1968.
11. Luers C, Sutcliffe A, Binder L, Irle S, et al. (2013). NT-proANP and NT-proBNP as prognostic markers in patients with acute decompensated heart failure of different etiologies. Clin. Biochem. 46: 1013-1019. http://dx.doi.org/10.1016/j. clinbiochem.2013.03.014
12. Mann DL and Young JB (1994). Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest 105: 897-904. http://dx.doi.org/10.1378/chest.105.3.897
13. Matsushita K, Iwanaga S, Oda T, Kimura K, et al. (2005). Interleukin-6/soluble interleukin-6 receptor complex reduces infarct size via inhibiting myocardial apoptosis. Lab. Invest. 85: 1210-1223. http://dx.doi.org/10.1038/ labinvest.3700322
14. Milovanovic M, Pesic G, Nikolic V, Jevtovic-Stoimenov T, et al. (2012). Vitamin D deficiency is associated with increased IL-17 and TNFa levels in patients with chronic heart failure. Arq. Bras. Cardiol. 98: 259-265. http://dx.doi. org/10.1590/S0066-782X2012005000019
15. Niu JM, Ma ZL, Xie C and Zhang ZQ (2014). Association of plasma B-type natriuretic peptide concentration with myocardial infarct size in patients with acute myocardial infarction. Genet. Mol. Res. 13: 6177-6183. http://dx.doi. org/10.4238/2014.February.21.6
16. Palazzuoli A, Caputo M, Calabrò A and Nuti R (2012). Clinical impact of BNP and other emerging biomarkers in heart failure evaluation and management. Minerva Cardioangiol. 60: 183-194.
17. Podewski EK, Hilfiker-Kleiner D, Hilfiker A, Morawietz H, et al. (2003). Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. Circulation 107: 798-802. http://dx.doi.org/10.1161/01.CIR.0000057545.82749.FF
18. Sanghi P, Uretsky BF and Schwarz ER (2005). Vasopressin antagonism: a future treatment option in heart failure. Eur. Heart J. 26: 538-543. http://dx.doi.org/10.1093/eurheartj/ehi145
19. Schwandner R, Yamaguchi K and Cao Z (2000). Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction. J. Exp. Med. 191: 1233-1240. http://dx.doi.org/10.1084/jem.191.7.1233
20. Scollan KF, Bulmer BJ and Sisson DD (2013). Validation of a commercially available enzyme immunoassay for measurement of plasma antidiuretic hormone concentration in healthy dogs and assessment of plasma antidiuretic hormone concentration in dogs with congestive heart failure. Am. J. Vet. Res. 74: 1206-1211. http://dx.doi. org/10.2460/ajvr.74.9.1206
21. Skiendzielewski J and Werner B (2014). The relevance of endothelin-1 in evaluation of the stage of heart failure in infants with ventricular septal defect. Kardiol. Pol. 72: 459-464. http://dx.doi.org/10.5603/KP.a2013.0351
22. Wuyts WA, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE, et al. (2005). Interleukin-17-induced interleukin-8 release in human airway smooth muscle cells: role for mitogen-activated kinases and nuclear factor-kappaB. J. Heart Lung Transplant. 24: 875-881. http://dx.doi.org/10.1016/j.healun.2004.05.003
23. Zhu SJ and Wang J (2001). Energy metabolic therapy can be used as a new target for treatment of heart failure. South China J. Crdiovascular Dis 2010: 97-98.